Sign in with Google. Opens in new tab
bullish
Sanofi (SAN FP): It Is Not Just Only Dupixent; New Drugs and Vaccine Launches to Augment Growth
Tina has highlighted this Insight as a Top Pick
409 Views02 Jul 2023 13:52
SUMMARY
- Sanofi (SAN FP) earns more than 20% revenue from its key growth driver, Dupixent. With expanding indications, Dupixent is on track to record €10B revenue in 2023.
- The company has added two new drugs in its portfolio this year. Since the beginning of 2023, Sanofi has reported five positive readouts for its pipeline.
- Sanofi aims to reach €10B vaccine sales by 2030 from €7B in 2022, fueled by accelerated pace of innovation. The company plans to launch RSV vaccine for infants this winter.
Related Insights
More »Loading
Trending Collections
More »Loading
Trending Insights
More »- Why Is LG CNS One of the Hottest Stocks in Korea in the Past One Month? Answer: Stablecoin Platform
- Hygon/Sugon Merger: BIG Index Flows on Completion
- Toyota Motor (7203 JP) Tactical Outlook: Uncertainty Persists, But Rebound Likely
- Ohayo Japan | Limited Retaliation to U.S. Strikes
- Quiddity Leaderboard ASX Sep25: Spartan-Ramelius Deal Consequences + Many High-Impact Index Changes
Top Unpaywalled Insights
More »Loading
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Loading...
x